|
|
|
市場調查報告書
對位性基因體:生物標記、診斷與治療的新契機
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
| 出版商 |
BCC Research |
| 出版日期 |
2010年03月 |
商品編碼 |
116932 |
| 內容資訊 |
英文 374 pages |
| 價格 |
|
|
對位性基因體:生物標記、診斷與治療的新契機 是由出版商BCC Research在2010年03月所出版的。
這份英文市場調查報告書包含374 pages 價格從美金4850起跳。
本報告針對全球對位性基因體市場進行全面性的分析，整理了生物標記、診斷、治療方面的新契機、到2014年為指的是場發展預測、應用領域、業界內的合併與併購等動向、參與企業概況等內容，其大綱如下所示。
第一章 前言
第二章 摘要
第三章 概述
- 介紹
- 對位性基因體的新範例
- 對位性基因體產品
- 研究工具與試劑
- 診斷
- 藥劑、其他
第四章 後生學技術
- 介紹
- 後生學(epigenetics）分析技術
- DNA及組織蛋白分析技術
- DNA甲基化作用、其他
第五章 後生學析技術
- 後生學研究工具的重要性
- DNA甲基化研究工具
- DNA甲基化工程、其他
第六章 後生學診斷技術
第七章 後生學癌症治療藥物技術
- 介紹
- 後生學與腫瘤生成
- 後生學酵素藥劑標的
- 組蛋白去乙醯酶抑制劑
- 組蛋白去乙醯酶抑制劑分級、其他
第八章 後生學分子選殖及細胞
- 體細胞核轉植技術
- 應用
- 再程式化因子（reprogramming factors）
- 細胞療法中品質管理分析
第九章 大型區域性對位性基因體計畫
第十章 癌症診斷方面的應用
第十一章 治療方面的應用
第十二章 市場成長促進因子
第十三章 市場分析
第十四章 對位性基因體計畫診斷市場
第十五章 後生學藥物市場
第十六章 細胞療法分析市場
第十七章 不同地區市場
第十八章 競合企業與業界趨勢
- 研究工具
- 診斷
- 後生學藥物產業
- 後生學產業中戰略性合夥
- 後生學產業中的併購動作
第十九章 專利
第二十章 企業概況
Abstract
THIS REPORT:
- Provides a comprehensive overview of the global market for epigenomics
- Describes the major epigenomics technologies impacting the market today
and emerging opportunities in biomarkers, diagnostics and therapeutics
- Contains global market forecasts for epigenomics, with trends and
forecasts for growth through 2014
- Offers a focus on particular applications of epigenomics, including
research tools, diagnostics, drugs and cloning/tissue engineering
- Discusses industry structure including, mergers and acquisitions,
distribution of products, government regulation and industry trends
- Profiles the most competitive businesses in the industry.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC' s goal for this study was to examine the status of commercial epigenomics
technologies and products and assess their worldwide growth potential over a
5-year period from 2009 to 2014. We analyzed the four important market
segments for epigenomics: research tools, diagnostics, therapeutics, and
assays for cellular therapies.
Our objective was to present a comprehensive discussion of where the
state-of-the-art is in epigenomics technologies and the current and future
commercial potential for these key market segments. We also wanted to study
current large-scale epigenome funding projects as well as the industry
competitive and patent dynamics.
REASONS FOR DOING THE STUDY
Epigenomics is a fast-growing biology field that is rapidly commercializing.
Epigenomics research tools and products enable discovery of novel diagnostic
biomarkers and drug targets. We previously examined the epigenetics market in
2007. Since that time, the FDA approved several epigenetic drugs for treating
non-Hodgkin' s lymphomas and myelodysplastic syndromes. In the past 2 years,
several epigenetic-based in-vitro diagnostics tests have been launched in the
United States and Europe for early colon cancer detection. A significant
number of additional drug candidates and diagnostics tests are in the clinical
pipeline and ready to be commercialized during our forecast horizon.
We are interested in determining the particular diseases for which
epigenomic-based diagnostics products will be used and the market and growth
potential for these applications. We are also interested in understanding the
scope of the future market potential for epigenetic drugs, including DNA
methylase inhibitors and histone deacetylase inhibitors.
It is particularly timely to examine the epigenomics industry in 2010 given
the changes in the industry and the increasing importance of gene regulation
beyond DNA sequence.
INTENDED AUDIENCE
We have compiled a study of important epigenomics technologies used in the
four major applications of research tools, diagnostics, therapeutics, and
cellular therapies. We define and describe the fundamental epigenomic
technologies, the market driving forces, product types, main market
applications, key companies, strategic alliances and acquisitions, future
global market potential and product sales forecasts for the period 2009
through 2014.
We analyze in detail the clinical pipelines for both epigenetic-based
diagnostics and therapeutics.
This study will be of particular interest to the molecular diagnostics
industry, pharmaceutical manufacturers, biotechnology companies, and life
science research tools companies. It will also be of interest to companies
involved in drug and/or biomarker discovery programs; manufacturers of
microarrays or next generation sequencing systems, high-grade antibodies,
restriction enzymes or primers; bioinformatics developers, and cancer
researchers and clinicians.
SCOPE OF REPORT
The study scope includes the major epigenomics technologies that are now, or
likely to become, commercialized within the next 5 years. We examine the
products flowing from these technologies, market segments into which these
products are sold, and we forecast product sales for the period 2009 through
2014. We describe factors that are driving growth in these markets.
Competitive dynamics and key trends in each of the market segments are
discussed.
We examine the strategies of successful companies, strategic alliances, and
the impact that large-scale epigenomic projects have on the industry. We
profile the major companies in the industry.
The scope of our analysis includes DNA methylation and histone acetylation and
methylation technologies; and the important market segments within research
tools, diagnostics, therapies, and cellular therapeutics. We are particularly
interested in cancer indications, which comprise the bulk of the diagnostics
and therapies markets.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
market research report. Included is an analysis of each of the four key market
segments that will be commercially important during the next 5 years: research
tools, cancer diagnostics, cancer therapeutics, and cellular therapies. We
examine each the important product types within these market segments, and
estimate the current and future sales from this perspective. We provide sales
revenue for 2008, 2009, and forecast growth through 2014 for each of these
segments.
For each of the market segments, we present market information for the
important products and technologies. For drugs and diagnostics, we present
market information by indication and by technology. For research tools, we
present market information by technology format and product type.
Table of Contents
Chapter-1: INTRODUCTION -- Complimentary 4
- STUDY GOALS AND OBJECTIVES 1
- REASONS FOR DOING THE STUDY 1
- INTENDED AUDIENCE 2
- SCOPE OF REPORT 2
- METHODOLOGY 2
- INFORMATION SOURCES 3
- RELATED BCC REPORTS 3
- BCC ONLINE SERVICES 3
- DISCLAIMER 4
Chapter-2: SUMMARY 3
- SUMMARY 5
- SUMMARY TABLE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH
2014 ($ MILLIONS) 6
- SUMMARY FIGURE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION,
2008-2014 ($ MILLIONS) 6
- SUMMARY (CONTINUED) 7
Chapter-3: OVERVIEW 17
- INTRODUCTION 8
- THE NEW PARADIGM OF EPIGENOMICS 8
- FIGURE 1 EPIGENOMICS: A NEW PARADIGM 9
- HOW EPIGENOMICS FITS WITHIN GENOMICS 10
- TABLE 1 GENOMICS PLATFORMS 10
- HOW EPIGENOMICS FITS WITHIN ... (CONTINUED) 11
- TECHNICAL SCOPE OF THIS REPORT 12
- TABLE 2 TECHNOLOGY SCOPE OF THIS REPORT 12
- MARKET POTENTIAL OF EPIGENOMICS 13
- TABLE 3 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014
($ MILLIONS) 13
- EPIGENOMICS PRODUCTS 14
- RESEARCH TOOLS AND REAGENTS 14
- DIAGNOSTICS 15
- DRUGS 15
- FIGURE 2 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND
INDICATION, JANUARY 2010 16
- GROWTH DRIVING FORCES 17
- GROWTH IN LIFE SCIENCE FUNDING 17
- CREATION OF EPIGENOMIC MAPS 17
- AGING POPULATION IN DEVELOPED COUNTRIES 17
- NEED FOR BETTER CANCER THERAPIES 17
- GROWTH IN PERSONALIZED MEDICINE 18
- WHY EPIGENETIC TECHNOLOGY IS IMPORTANT 18
- FIGURE 3 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL
DEVELOPMENT 18
- LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES 19
- HISTORICAL BACKGROUND 20
- TABLE 4 HISTORICAL OVERVIEW OF EPIGENOMICS 20
- HISTORICAL BACKGROUND (CONTINUED) 21
- THE EPIGENOMICS INDUSTRY 22
- TABLE 5 EPIGENOMICS INDUSTRY KEY COMPANIES 23
- THE EPIGENOMICS INDUSTRY (CONTINUED) 24
Chapter-4: EPIGENETIC TECHNOLOGIES 16
- INTRODUCTION 25
- EPIGENETIC ANALYSIS TECHNOLOGIES 25
- TABLE 6 EPIGENETIC ANALYSIS TECHNOLOGIES 26
- STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES 26
- TABLE 7 STATUS OF DNA METHYLATION AND HISTONE ANALYSIS TECHNOLOGIES 26
- TABLE 7 (CONTINUED) 27
- DNA AND HISTONE ANALYSIS WORKFLOW 28
- FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS WORKFLOW 29
- DNA METHYLATION 29
- METHYLATED CYTOSINE - A FIFTH BASE 29
- FIGURE 5 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 30
- BIOLOGICAL ROLE OF DNA METHYLATION 30
- TABLE 8 BIOLOGICAL ROLES OF DNA METHYLATION 31
- DNA METHYLTRANSFERASE ENZYMES 32
- CPG ISLANDS 33
- TABLE 9 DESCRIPTION OF CPG ISLANDS 34
- HISTONE METHYLATION AND ACETYLATION 35
- HISTONES 35
- HISTONE MODIFICATIONS 36
- FIGURE 6 ACETYLATION OF HISTONE TAIL REGIONS 36
- HISTONE ACETYLATION AND METHYLATION ENZYMES 37
- FIGURE 7 HISTONE ACETYLATION AND METHYLATION ENZYMES 38
- Histone Acetyl Transferases (HAT) 38
- Histone Deacetylases (HDAC) 39
- TABLE 10 HDAC ENZYMES CLASSES 39
- Histone Methyltransferases and Demethylases 39
- INAPPROPRIATE METHYLATION AND ACETYLATION 40
- TABLE 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION 40
Chapter-5: EPIGENOMIC ANALYSIS TECHNOLOGIES 40
- IMPORTANCE OF EPIGENOMIC RESEARCH TOOLS 41
- DNA METHYLATION RESEARCH TOOLS 42
- TABLE 12 DNA METHYLATION ANALYSIS ASSAYS 42
- DNA METHYLATION RESEARCH TOOLS (CONTINUED) 43
- TABLE 13 EMERGING DNA METHYLATION TECHNOLOGIES 44
- TABLE 14 ACROYNMS FOR DNA METHYLATION TECHNOLOGIES 45
- DNA METHYLATION ANALYSIS WORKFLOW 46
- FIGURE 8 METHYLATED DNA ANALYSIS WORKFLOW 47
- DNA METHYLATION ANALYSIS METHODS BY COVERAGE AND THROUGHPUT 47
- TABLE 15 DNA METHYLATION TECHNOLOGIES BY COVERAGE AND THROUGHPUT 48
- DNA METHYLATION ANALYSIS TYPES BY WORKFLOW 49
- TABLE 16 EXAMPLES OF DNA METHYLATION ASSAYS 49
- DNA METHYLATION ANALYSIS: UPSTREAM TECHNOLOGIES 50
- TABLE 17 METHYLATION RECOGNITION TECHNOLOGIES 50
- RESTRICTION ENZYME-BASED METHODS 51
- FIGURE 9 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES 52
- BISULFITE-BASED METHODS 52
- Bisulfite-based Methods (Continued) 53
- FIGURE 10 BISULFITE CONVERSION OF DNA 54
- Analysis of Low Complexity DNA 55
- AFFINITY-BASED METHODS 56
- CHALLENGE OF HIGH BACKGROUND METHYLATED DNA 57
- GENOME WIDE DNA METHYLATION ANALYSIS 57
- TABLE 18 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION 58
- HISTONE EPIGENETIC ANALYSIS TECHNOLOGIES 59
- TABLE 19 CHIP ASSAYS 60
- CHIP - CHIP AND CHIP-SEQ 61
- FIGURE 11 WORKFLOW SCHEMATIC FOR CHIP PLATFORMS 61
- TABLE 20 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS
AND ENZYMES 62
- EMERGING DOWNSTREAM EPIGENETIC ANALYSIS PLATFORMS 63
- MICROARRAYS 63
- TABLE 21 MICROARRAY TYPES 63
- TABLE 22 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 64
- DNA Microarray Technologies 65
- FIGURE 12 MICROARRAY FEATURE DENSITY 66
- FIGURE 13 MICROARRAY RESOLUTION 66
- TABLE 23 MICROARRAY GENOME CONTENT 67
- TABLE 24 DNA MICROARRAY PLATFORM FEATURES 68
- TABLE 25 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 69
- DNA Microarray ... (Continued) 70
- Microarrays for Epigenetics Analysis 71
- FIGURE 14 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS
ASSAYS 71
- Microarrays for ... (Continued) 72
- NEXT GENERATION DNA SEQUENCING 73
- FIGURE 15 DNA SEQUENCING PLATFORMS 73
- Next Generation DNA ... (Continued) 74
- Next Generation DNA ... (Continued) 75
- FIGURE 16 NEXT GENERATION SEQUENCING TECHNOLOGIES WORKFLOW OVERVIEW 76
- SERIAL ANALYSIS OF GENE EXPRESSION 77
- ANTIBODIES 78
- ALTERNATIVES TO ANTIBODIES IN UPSTREAM ANALYSIS STEP 79
- ALTERNATIVES TO ANTIBODIES IN ... (CONTINUED) 80
Chapter-6: EPIGENETICS DIAGNOSTICS TECHNOLOGIES 21
- WHAT IS A BIOMARKER?
- TABLE 26 ROLE OF BIOMARKERS IN CLINICAL TRIAL DESIGN
- DNA METHYLATION AS A CANCER BIOMARKER
- DNA METHYLATION IN CANCER ETIOLOGY
- TABLE 27 BIOLOGICAL RATIONALE FOR DNA METHYLATION CANCER BIOMARKERS
- TABLE 28 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY
HYPER-METHYLATION
- Cell Cycle Control
- Cell Invasion and Adhesion
- DNA Damage Repair
- Growth Factor Response
- Regulation of Apoptosis
- Hormonal Response
- Cytokine Signaling
- TABLE 29 CANCER-RELATED EPIGENETIC CHANGES
- COMPARISON OF MOLECULAR BIOMARKER PLATFORMS
- TABLE 30 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS
- Comparison of Molecular ... (Continued)
- Comparison of Molecular ... (Continued)
- ASSESSMENT OF DNA METHYLATION BIOMARKER COMPETITIVE POSITION
- EPIGENETIC BIOMARKER GENES
- TABLE 31 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS
- TABLE 32 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR
DISORDERS
- BIOMARKER DISCOVERY PROCESS
- METHYLATION BIOMARKER DISCOVERY TECHNOLOGIES
- TABLE 33 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY
- GENOME-WIDE SCANNING FOR BIOMARKER DISCOVERY
- CASE STUDY: FROM RESEARCH TOOLS TO BIOMARKERS
- IN-VITRO DIAGNOSTIC DEVELOPMENT PROCESS
- PHASE 1: BIOMARKER DISCOVERY
- PHASE 2: BIOMARKER VALIDATION
- PHASE 3: FORMAL KIT DEVELOPMENT
- PHASE 4: CLINICAL VALIDATION
- PHASE 5: REGULATORY REVIEW AND APPROVAL
- FUTURE STATUS OF DNA METHYLATION BIOMARKERS
- TABLE 34 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC
CANCER BIOMARKERS
- FUTURE STATUS OF DNA ... (CONTINUED)
Chapter-7: EPIGENETIC CANCER DRUG TECHNOLOGIES 27
- INTRODUCTION 102
- EPIGENETICS IN TUMORIGENESIS 102
- EPIGENETIC GENES IN HUMAN CANCER 102
- TABLE 35 EPIGENETIC GENES ALTERED IN HUMAN CANCERS 103
- TABLE 35 (CONTINUED) 104
- EPIGENETIC ENZYME DRUG TARGETS 105
- FIGURE 17 HISTONE DEACETYLASE REACTION 105
- TABLE 36 STATUS OF INHIBITORS OF EPIGENETIC ENZYMES TARGETING HISTONES 106
- HISTONE DEACETYLASE INHIBITORS 107
- BENEFITS OF HDAC INHIBITORS 108
- HDAC INHIBITOR DRUG CLASSES 109
- TABLE 37 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY 109
- Hydroxamates 110
- FIGURE 18 CHEMICAL STRUCTURE OF TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC
INHIBITOR 110
- Aliphatic Acids 110
- FIGURE 19 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR 111
- Cyclic Tetrapeptides 111
- FIGURE 20 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR 111
- Benzamides 112
- FIGURE 21 ENTINOSTAT, A BENZAMIDE CLASS HDAC INHIBITOR 112
- HDAC INHIBITOR TECHNOLOGY TRENDS 113
- TABLE 38 HDAC INHIBITOR DRUG TECHNOLOGY TRENDS 113
- Enzyme Selectivity 113
- Enzyme Selectivity (Continued) 114
- TABLE 39 HDAC INHIBITOR CLASS I AND II SELECTIVITY 115
- Potency 115
- Improvements in Drug-like Properties 116
- SELECTIVE HDAC COMPOUNDS CAN PROVIDE COMPETITIVE ADVANTAGE 116
- FIGURE 22 DISEASE HDAC ISOFORM GENE EXPRESSION PROFILE 117
- CHEMICAL DESIGN IS THE KEY TO HDAC INHIBITOR SELECTIVITY 118
- FIGURE 23 COMMON STRUCTURAL COMPONENT MOTIFS OF VORINOSTAT 118
- Chemical Design ... (Continued) 119
- HDAC INHIBITORS IN COMBINATION THERAPIES 120
- TABLE 40 DRUG CLASSES THAT CAN BE USED IN COMBINATION WITH HDAC INHIBITORS
121
- HDAC INHIBITORS AS THERAPIES OUTSIDE CANCER 122
- DERMATOLOGICAL DISORDERS 123
- PARASITIC DISEASES 123
- NEURODEGENERATIVE DISEASES 124
- DIABETES 125
- INFLAMMATORY DISEASES 125
- IMMUNE DISORDERS 125
- DNA METHYLTRANSFERASE INHIBITORS 126
- FIGURE 24 LEAD DNMT INHIBITOR COMPOUNDS 126
- TECHNICAL CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 127
- TABLE 41 FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 127
- TECHNICAL CHALLENGES FOR ... (CONTINUED) 128
Chapter-8: EPIGENETICS CLONING AND CELLULAR 8
- SOMATIC CELL NUCLEAR TRANSFER 129
- FIGURE 25 SOMATIC CELL NUCLEAR TRANSFER 129
- TABLE 42 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER 130
- APPLICATIONS 130
- REPROGRAMMING FACTORS 131
- FIGURE 26 EPIGENETIC PROGRAMMING OF STEM CELLS 132
- QUALITY CONTROL ASSAYS IN CELLULAR THERAPIES 132
- Tissue Engineering 133
- Stem Cell Therapies 133
- Non-stem Cell Therapies 134
Chapter-9: LARGE SCALE REGIONAL EPIGENOMICS PROJECTS 6
- LARGE SCALE REGIONAL EPIGENOMICS PROJECTS 135
- TABLE 43 REGIONAL EPIGENOMICS INITIATIVES 136
- TABLE 43 (CONTINUED) 137
- EUROPE 137
- UNITED STATES 138
- ASIA 139
- Asia (Continued) 140
Chapter-10: CANCER DIAGNOSTICS APPLICATIONS 30
- ATTRACTIVE CANCER INDICATIONS FOR SCREENING MARKETS 141
- FIGURE 27 CANCER SCREENING OPPORTUNITY MATRIX FOR MOLECULAR DIAGNOSTICS 142
- EPIGENETICS AS A SCREENING PLATFORM 143
- FIGURE 28 NEW EPIGENETIC SCREENING PARADIGM 144
- DIAGNOSTIC SENSITIVITY AND SPECIFICITY 144
- FIGURE 29 SENSITIVITY AND SPECIFICITY 145
- STATUS OF DIAGNOSTICS TESTS FOR SELECTED CANCER INDICATIONS 146
- BLADDER CANCER 146
- CARCINOMA OF UNKNOWN PRIMARY (CUP) 147
- TABLE 44 COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS FOR TISSUE OF ORIGIN
TESTS 148
- CERVICAL CANCER 149
- TABLE 45 COMMERCIAL LANDSCAPE FOR HPV TESTS 150
- Cervical Cancer (Continued) 151
- COLORECTAL CANCER 152
- Colorectal Cancer Existing Screening Tests 152
- TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 153
- TABLE 47 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS 154
- Molecular Colorectal Cancer Diagnostics Tests 155
- TABLE 48 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 155
- Molecular ... (Continued) 156
- TABLE 49 COMPETITIVE SITUATION FOR CONVENTIONAL AND MOLECULAR COLON CANCER
SCREENING TESTS 157
- Colorectal Cancer Diagnostics Tests 158
- GASTRIC CANCER 158
- LUNG CANCER 159
- Lung Cancer (Continued) 160
- OVARIAN CANCER 161
- TABLE 50 OVARIAN CANCER SCREENING TESTS 161
- TABLE 51 OVARIAN CANCER DIAGNOSTIC TEST STATUS 162
- PANCREATIC CANCER 163
- PEDIATRIC CANCERS 163
- PROSTATE CANCER 164
- Prostate Cancer (Continued) 165
- PERSONALIZED TREATMENT EPIGENETIC-BASED TESTS 166
- KEY CLINICAL REQUIREMENTS FOR AN EPIGENETIC-BASED DIAGNOSTICS TEST 166
- TABLE 52 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 167
- DNA METHYLATION DIAGNOSTICS PIPELINE 168
- TABLE 53 EPIGENETIC DIAGNOSTICS DEVELOPMENT PIPELINE 168
- TABLE 53 (CONTINUED) 169
- DNA METHYLATION DIAGNOSTICS ... (CONTINUED) 170
Chapter-11: THERAPEUTIC APPLICATIONS 17
- EPIGENETIC DRUG CLINICAL TRIALS 171
- TABLE 54 APPROVED EPIGENETIC DRUGS 171
- TABLE 55 NEXT GENERATION EPIGENETIC DRUGS 171
- FIGURE 30 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY DRUG CLASS AND
CANCER TYPE, JANUARY 2010 172
- FIGURE 30 (CONTINUED) 173
- FIGURE 31 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND
INDICATION, JANUARY 2010 174
- FIGURE 32 CURRENT EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY DRUG AND
TRIAL TYPE, JANUARY 2010 175
- FIGURE 33 ACTIVE EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY CLINICAL PHASE
AND TRIAL TYPE, JANUARY 2010 176
- EPIGENETIC DRUG NOMENCLATURE 177
- TABLE 56 EPIGENETIC DRUG NOMENCLATURE TABLE 177
- TABLE 56 (CONTINUED) 178
- HDAC INHIBITOR CLINICAL TRIALS 178
- TABLE 57 HDAC INHIBITOR CLINICAL TRIALS SUMMARY 178
- TABLE 57 (CONTINUED) 179
- HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 179
- HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 180
- TABLE 58 MBCD0103 INHIBITS SELECTED HDAC ENZYMES 181
- HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 182
- DNMT INHIBITORS CLINICAL TRIALS 183
- TABLE 59 DNMT INHIBITOR CLINICAL TRIALS SUMMARY 183
- DNMT INHIBITORS CLINICAL TRIALS (CONTINUED) 184
- EPIGENETIC DRUGS FOR NON-CANCER INDICATIONS 185
- TABLE 60 EPIGENETIC NON-CANCER DRUG LANDSCAPE 186
- EPIGENETIC DRUGS FOR NON-CANCER ... (CONTINUED) 187
Chapter-12: MARKET GROWTH DRIVING FORCES 7
- EPIGENETICS SCIENTIFIC PUBLICATIONS 188
- FIGURE 34 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS (NUMBER
OF PUBLICATIONS) 188
- GROWTH DRIVING FORCES 189
- TABLE 61 FORCES DRIVING EPIGENOMICS INDUSTRY GROWTH 189
- GROWTH IN FUNDING FOR LIFE-SCIENCE RESEARCH 189
- TABLE 62 STIMULUS FUNDING ALLOCATED TO UNITED STATES SCIENCE SPENDING 190
- FIGURE 35 ANNUAL NIH FUNDING BUDGET, 2000-2009 ($ MILIONS) 190
- FIGURE 35 (CONTINUED) 191
- CREATION OF EPIGENETIC MAPS 191
- RANGE OF OCCURRENCE OF EPIGENETIC CHANGES 192
- AGING POPULATIONS IN DEVELOPED COUNTRIES 192
- NEED FOR BETTER CANCER THERAPIES 193
- GROWTH IN PERSONALIZED MEDICINE 193
- UNDERSTANDING OF EPIGENETIC PROCESSES BEYOND CANCER 194
Chapter-13: MARKET ANALYSIS 17
- MARKET SUMMARY 195
- TABLE 63 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014
($ MILLIONS) 195
- MARKET SUMMARY (CONTINUED) 196
- TABLE 64 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY GEOGRAPHY, THROUGH 2014
($ MILLIONS) 197
- RESEARCH TOOLS MARKETS 197
- GLOBAL SALES BY PRODUCT 197
- TABLE 65 GLOBAL VALUE OF EPIGENOMIC ANALYSIS RESEARCH TOOLS, BY PRODUCT
TYPE, THROUGH 2014 ($ MILLIONS) 198
- Kits 198
- Reagents 198
- Microarrays and Next Gen Sequencing 198
- Microarrays and ... (Continued) 199
- EPIGENOMIC KIT SALES BY TECHNOLOGY 200
- TABLE 66 GLOBAL VALUE OF EPIGENOMICS RESEARCH TOOLS KITS, BY TECHNOLOGY,
THROUGH 2014 ($ MILLION) 200
- Epigenomic Kit ... (Continued) 201
- TABLE 67 GLOBAL VALUE OF EPIGENOMIC ANALYSIS KITS, BY FORMAT, THROUGH 2014
($ MILLIONS) 202
- DNA METHYLATION ANALYSIS KIT MARKET 202
- DNA Methylation ... (Continued) 203
- TABLE 68 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY ANALYSIS
OBJECTIVE, THROUGH 2014 ($ MILLIONS) 204
- TABLE 69 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY
TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 205
- TABLE 70 GLOBAL VALUE OF DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS,
BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 206
- TABLE 71 GLOBAL VALUE OF DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS
BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 207
- HISTONE ANALYSIS KIT MARKET 208
- TABLE 72 GLOBAL VALUE OF HISTONE ANALYSIS KITS, BY TECHNOLOGY FORMAT,
THROUGH 2014 ($ MILLIONS) 208
- EPIGENETICS MICROARRAY MARKETS 208
- MICROARRAYS AND NEXT GEN SEQUENCING AS DOWNSTREAM TOOLS 209
- MICROARRAY MARKET 209
- TABLE 73 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS, BY APPLICATION, THROUGH
2014 ($ MILLIONS) 210
- RESEARCH TOOLS REAGENTS MARKET 211
- TABLE 74 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS, BY
TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 211
Chapter-14: EPIGENOMIC DIAGNOSTICS MARKET 8
- OVERVIEW OF CANCER DIAGNOSTICS MARKET 212
- TABLE 75 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS PRODUCTS, BY APPLICATION,
THROUGH 2014 ($ MILLIONS) 212
- CANCER MOLECULAR DIAGNOSTICS GROWTH DRIVERS 213
- EPIGENETICS-BASED DIAGNOSTICS MARKETS 213
- TABLE 76 PROJECTED CHANGE IN AGE 65-PLUS POPULATION BY REGION (%) 214
- Epigenetics-based ... (Continued) 215
- TABLE 77 U.S. CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2009 216
- TABLE 78 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY APPLICATION,
THROUGH 2014 ($ MILLIONS) 217
- TABLE 79 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY CANCER
INDICATION, THROUGH 2014 ($ MILLIONS) 218
- Epigenetics-based ... (Continued) 219
Chapter-15: EPIGENETIC DRUGS MARKETS 25
- OVERVIEW 220
- CANCER DRUG MARKET GROWTH DRIVING FORCES 220
- CANCER DRUG MARKET ... (CONTINUED) 221
- CLINICAL PROOF OF PRINCIPLE OF EPIGENETIC DRUGS IS ESTABLISHED 222
- EPIGENETIC THERAPIES BEYOND CANCER 223
- EPIGENETIC DRUG MARKET SUMMARY 223
- TABLE 80 GLOBAL VALUE OF EPIGENETIC DRUGS, BY CANCER INDICATION, THROUGH
2014 ($ MILLIONS) 224
- Hematological 224
- Hematological (Continued) 225
- Solid Tumors 226
- Solid Tumors (Continued) 227
- Solid Tumors (Continued) 228
- EPIGENETIC DRUG MARKET BY DRUG CLASS 229
- TABLE 81 GLOBAL VALUE OF EPIGENETIC DRUGS, BY DRUG CLASS, THROUGH 2014 ($
MILLIONS) 229
- HDAC INHIBITORS MARKETS 229
- Strategic Opportunities in HDAC Inhibitors 230
- TABLE 82 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER
TREATMENT 230
- HDAC Inhibitor Drug Market Size by Indication 231
- TABLE 83 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY INDICATION, THROUGH 2014
($ MILLIONS) 232
- HDAC Inhibitor Market Size by Technology 233
- TABLE 84 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014
($ MILLIONS) 233
- DNMT INHIBITORS MARKET 234
- TABLE 85 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY INDICATION, THROUGH 2014
($ MILLIONS) 235
- TABLE 86 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014
($ MILLIONS) 236
- HEMATOLOGICAL CANCER EPIGENETIC DRUG MARKET 236
- OVERVIEW OF HEMATOLOGICAL CANCERS 236
- TABLE 87 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES 237
- Overview of Hematological Cancers (Continued) 238
- TABLE 88 MDS DRUG COMPARISON 239
- HEMATOLOGICAL DRUG MARKET BY INDICATION 240
- TABLE 89 HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH
2014 ($ MILLIONS) 240
- HDAC Hematological Drug Market 241
- TABLE 90 HDAC HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION,
THROUGH 2014 ($ MILLIONS) 241
- HDAC Hematological ... (Continued) 242
- TABLE 91 COMPARISON OF THE PTCL DRUGS, FOLYTYN AND ISTODAX 243
- DNMT Hematological Drug Market 243
- TABLE 92 DNMT HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION,
THROUGH 2014 ($ MILLIONS) 244
Chapter-16: CELL THERAPY ASSAYS MARKETS 2
- TABLE 93 EPIGENETIC CELL THERAPIES MARKETS, BY APPLICATION, THROUGH 2014
($ MILLIONS) 245
- CELL THERAPY ASSAYS MARKETS (CONTINUED) 246
Chapter-17: GEOGRAPHICAL MARKETS 4
- TABLE 94 EPIGENOMIC RESEARCH TOOLS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($
MILLIONS) 247
- TABLE 95 EPIGENOMIC DIAGNOSTICS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($
MILLIONS) 248
- TABLE 96 NUMBER OF HOSPITALS AND CLINICS, BY GEOGRAPHICAL REGION 248
- TABLE 97 EPIGENOMIC PHARMACEUTICALS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($
MILLIONS) 249
- TABLE 98 EPIGENOMIC CELL THERAPIES MARKETS, BY GEOGRAPHY, THROUGH 2014 ($
MILLIONS) 250
Chapter-18: COMPETITOR AND INDUSTRY DYNAMICS 19
- RESEARCH TOOLS 251
- TABLE 99 SCOPE OF EPIGENOMIC RESEARCH TOOLS SUPPLIERS 252
- FIGURE 36 CHIP-GRADE ANTIBODY SUPPLIER MARKET SHARES, 2009 (%) 253
- FIGURE 36 (CONTINUED) 254
- DIAGNOSTICS 254
- SKILL SET FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 254
- SHIFTING PARADIGM IN DIAGNOSTICS 255
- IN-VITRO DIAGNOSTICS COMPETITORS 256
- TABLE 100 IN-VITRO DIAGNOSTICS COMPETITORS 256
- In-Vitro Diagnostics ... (Continued) 257
- TABLE 101 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS
DIAGNOSTICS FIRMS 258
- TABLE 102 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES 259
- EPIGENETIC DRUGS INDUSTRY 259
- TABLE 103 RELATIVE STRATEGIC POSITION FOR EPIGENOMIC DRUG COMPANIES 260
- FIGURE 37 EPIGENOMIC DRUG COMPANY MARKET SHARES, 2009 261
- EPIGENOMIC INDUSTRY STRATEGIC ALLIANCES 262
- TABLE 104 EPIGENOMICS STATEGIC ALLIANCES: 2007-2010 263
- TABLE 104 (CONTINUED) 264
- EPIGENOMIC INDUSTRY ... (CONTINUED) 265
- EPIGENOMIC INDUSTRY ... (CONTINUED) 266
- EPIGENOMICS INDUSTRY ACQUISITIONS 267
- TABLE 105 EPIGENOMICS INDUSTRY ACQUISITIONS, 2007 - 2010 268
- EPIGENOMICS INDUSTRY ... (CONTINUED) 269
Chapter-19: PATENTS 13
- EPIGENOMICS PATENT ACTIVITY 270
- FIGURE 38 NUMBER OF EPIGENOMICS PATENTS, BY YEAR, 2000-2009 270
- FIGURE 39 NUMBER OF EPIGENOMICS PATENTS, BY GEOGRAPHY, 2000 - 2009 271
- FIGURE 39 (CONTINUED) 272
- RESEARCH TOOLS AND DIAGNOSTICS PATENT ACTIVITY 272
- TABLE 106 EPIGENOMICS AG RESEARCH TOOLS PATENT COVERAGE 272
- RESEARCH TOOLS AND ... (CONTINUED) 273
- FIGURE 40 BIOTECHNOLOGY DIAGNOSTICS PATENTS, BY COMPANY (%) 274
- TABLE 107 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 275
- PHARMACEUTICALS PATENTS ACTIVITY 276
- TABLE 108 HDAC INHIBITOR PATENT CLAIMS, 2004 - 2006 276
- TABLE 108 (CONTINUED) 277
- FIGURE 41 NUMBER OF EPIGENOMICS DRUG PATENTS, BY TECHNOLOGY CLASS AND
GEOGRAPHY 278
- PHARMACEUTICALS PATENTS ACTIVITY (CONTINUED) 279
- FIGURE 42 NUMBER OF HDAC INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY 280
- FIGURE 43 NUMBER OF DNMT INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY 281
- PATENT CASE STUDIES 282
Chapter-20: COMPANY PROFILES 90
- ABBOTT LABORATORIES 283
- ABCAM PLC. 284
- ACCESS PHARMACEUTICALS 285
- ACETYLON PHARMACEUTICALS 286
- ACTIVE MOTIF 286
- AFFYMETRIX, INC. 287
- AFFYMETRIX, INC. (CONTINUED) 288
- TABLE 109 AFFYMETRIX STRATEGIC ALLIANCES 289
- TABLE 109 (CONTINUED) 290
- AGILENT TECHNOLOGIES, INC. 291
- ARNO THERAPEUTICS, INC. 292
- ARUP LABORATORIES, INC. 293
- ASTELLAS PHARMA, INC. 293
- BAYER AG 294
- BIOFIELD CORP. 295
- BIOSERVE BIOTECHNOLOGIES, LTD. 295
- BIOVISION 295
- CELGENE CORPORATION 296
- CELGENE CORPORATION (CONTINUED) 297
- CELLARTIS AB 298
- CELLCENTRIC LTD. 298
- CELLERON THERAPEUTICS LTD. 299
- CELLZOME AG 300
- CHIPSCREEN BIOSCIENCES LTD. 301
- CHROMA THERAPEUTICS LTD. 302
- CLAVIS PHARMA ASA 302
- TABLE 110 CLAVIS PHARMA DRUG PIPELINE 303
- CONSTELLATION PHARMACEUTICALS 304
- CRYSTAL GENOMICS, INC. 304
- CURIS 305
- EISAI CO. LTD. 305
- EPIGENOMICS AG 306
- EPIGENOMICS AG (CONTINUED) 307
- EPIGENTEK 308
- EPITHERAPEUTICS 309
- ELIXIR PHARMACEUTICALS, INC. 309
- ENVIVO PHARMACEUTICALS 310
- EOS SPA 311
- EPIONTIS GMBH 311
- EPIZYME, INC. 312
- ES CELL INTERNATIONAL PTE LTD 313
- EXONHIT THERAPEUTICS SA 313
- F. HOFFMANN-LA ROCHE, LTD. 314
- GENEXTRA S.P.A 315
- GENPATHWAY, INC. 316
- GLAXOSMITHKLINE 316
- GLAXOSMITHKLINE (CONTINUED) 317
- HUYA BIOSCIENCE INTERNATIONAL 318
- ILLUMINA, INC. 319
- ILLUMINA, INC. (CONTINUED) 320
- TABLE 111 ILLUMINA SEQUENCING TECHNOLOGY SPACE 321
- IMAGENES GMBH 322
- INTERNATIONAL DRUG DISCOVERY INSTITUTE 323
- ITALFARMACO SPA 323
- JOHNSON & JOHNSON 324
- KARUS THERAPEUTICS LTD. 325
- LABORATORY CORPORATION OF AMERICA HOLDINGS 326
- LES LABORATOIRES SERVIER 327
- LIFE TECHNOLOGIES INC. 328
- LIFE TECHNOLOGIES INC. (CONTINUED) 329
- MERCK KGAA 330
- MERCK & CO. INC. 331
- METHYLGENE 332
- TABLE 112 METHYLGENE HDAC INHIBITOR PRODUCT PIPELINE 333
- MILLIPORE 334
- NATUREWISE BIOTECH & MEDICALS CORP. 335
- NOVARTIS 336
- ONCOLYS BIOPHARMA INC. 337
- ONCOMETHYLOME SCIENCES S.A. 338
- TABLE 113 ONCOMETHYLOME DNA METHYLATION DIAGNOSTICS PIPELINE 339
- ONCOMETHYLOME SCIENCES S.A. (CONTINUED) 340
- ORCHID CHEMICALS & PHARMACEUTICALS LIMITED 341
- ORION GENOMICS 342
- TABLE 114 ORION STRATEGIC ALLIANCES 343
- TABLE 115 ORION EPIGENETIC DIAGNOSTICS PIPELINE 344
- ORTHO BIOTECH 345
- PACIFIC BIOSCIENCES 345
- PHARMACYCLICS 346
- PROGEN PHARMACEUTICALS LTD. 347
- PROGEN PHARMACEUTICALS LTD. (CONTINUED) 348
- PROGNOSDX HEALTH, INC. 349
- QUEST DIAGNOSTICS 349
- ROCHE LIFE SCIENCES 350
- ROCHE LIFE SCIENCES (CONTINUED) 351
- ROCHE LIFE SCIENCES (CONTINUED) 352
- QIAGEN GMBH 353
- RAINDANCE TECHNOLOGIES 354
- REACTION BIOLOGY CORP. 354
- REPLIGEN CORPORATION 355
- RUBICON GENOMICS 355
- RUBICON GENOMICS (CONTINUED) 356
- S*BIO PTE LTD 357
- TABLE 116 S*BIO HDAC INHIBITOR DRUG PIPELINE 358
- SCHERING PLOUGH CORPORATION 358
- SCOTTISH BIOMEDICAL LTD. 359
- SEQUENOM, INC. 360
- SEQUENOM, INC. (CONTINUED) 361
- SEQWRIGHT 362
- SUPERGEN, INC. 362
- SYNDAX PHARMACEUTICALS, INC. 363
- TABLE 117 ENTINOSTAT CLINICAL TRIALS SUMMARY STATUS 363
- SYSMEX CORPORATION 364
- TAIHO PHARMACEUTICALS 365
- TAKEDA PHARMACEUTICAL COMPANY LIMITED 365
- TARGECEPT, INC. 366
- THEREPI INC. 366
- TOPOTARGET A/S 366
- TOPOTARGET A/S (CONTINUED) 367
- TOPOTARGET A/S (CONTINUED) 368
- TABLE 118 TOPOTARGET' S HDAC INHIBITOR PATENT PORTFOLIO 369
- VALIBIO SA 370
- VALIRX 371
- VERIDEX LLC 371
- ZYMO RESEARCH 372
|
 |
